Related references
Note: Only part of the references are listed.Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
Michael A. Bauer et al.
HAEMATOLOGICA (2021)
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Sarah Gooding et al.
BLOOD (2021)
Splicing to Keep Cycling: The Importance of Pre-mRNA Splicing during the Cell Cycle
Mayra Petasny et al.
TRENDS IN GENETICS (2021)
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Vikas A. Gupta et al.
BLOOD (2021)
Splicing factor mutations in hematologic malignancies
Sisi Chen et al.
BLOOD (2021)
Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines
Joana Jorge et al.
INVESTIGATIONAL NEW DRUGS (2020)
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Sophia Adamia et al.
LEUKEMIA (2020)
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
Hector H. Huang et al.
NATURE COMMUNICATIONS (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Amino acid depletion triggered by.-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
Debora Soncini et al.
BLOOD ADVANCES (2020)
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al.
LEUKEMIA (2019)
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Dana Prukova et al.
CLINICAL CANCER RESEARCH (2019)
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators
Daniel Aird et al.
NATURE COMMUNICATIONS (2019)
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
Anne Slomp et al.
BLOOD ADVANCES (2019)
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
A. Lagana et al.
LEUKEMIA (2018)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
Identification of pathway-based prognostic gene signatures in patients with multiple myeloma
Mohamad Zamani-Ahmadmahmudi et al.
TRANSLATIONAL RESEARCH (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Therapeutics targeting Bcl-2 in hematological malignancies
Astrid Ruefli-Brasse et al.
BIOCHEMICAL JOURNAL (2017)
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Matteo Marchesini et al.
CANCER CELL (2017)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
Michele Cea et al.
BLOOD (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Therapeutic targeting of splicing in cancer
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Tiffany Y. -T. Hsu et al.
NATURE (2015)
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
Cheryl M. Koh et al.
NATURE (2015)
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Sarah L. Maguire et al.
JOURNAL OF PATHOLOGY (2015)
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
Sophia Adamia et al.
BLOOD (2014)
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
D. S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2014)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer
Thomas R. Webb et al.
DRUG DISCOVERY TODAY (2013)
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Timothy A. Graubert et al.
NATURE GENETICS (2012)
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
Victor Quesada et al.
NATURE GENETICS (2012)
The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region
Eric G. Folco et al.
GENES & DEVELOPMENT (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Yoshihiko Kotake et al.
NATURE CHEMICAL BIOLOGY (2007)
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Daisuke Kaida et al.
NATURE CHEMICAL BIOLOGY (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
How did alternative splicing evolve?
G Ast
NATURE REVIEWS GENETICS (2004)
Share Paper
